The purpose of the study is to assess the experiences of individuals with acromegaly who are receiving injections as part of their treatment regimen. Another objective of the study is to compare the patients' perception with their doctors' perceptions. The answers are important to help researchers and physicians understand what it is really like to take currently available treatments so that they can make efforts to improve patients' healthcare experiences, reduce treatment burden and, ultimately, improve patient's quality of life.

Inclusion Criteria:

• Age >=18 years-old and <95 years-old
• Patient self-reported acromegaly diagnosis which will be further confirmed by a knowledge screening based on current medications and doses
• Currently on injectable Somatostatin analogues (SSA), Sandostatin® LAR or Somatuline® Depot, for >=12 months
• Have not had a change in dosage of their acromegaly treatment at the time of or since their last office visit
• Have seen their treating acromegaly physician within the past 12 +/-2 months NOTE: This timeframe allows two additional months for scheduling an appointment with their physician, since most patients should see their acromegaly physician at least once every 12 months
• Ability to read and understand English
• Live and receive acromegaly treatments in the US
• Willing to provide signed informed consent

Exclusion Criteria:

• Previous or current participant in Mycapssa® (octreotide capsules) trial
• Use of Pegvisomant (Somavert®) monotherapy
• Use of Pasireotide (Signifor®)

Patients diagnosed with acromegaly will be sent invitations to participate. Their physicians will be identified at the time of participant enrollment and will be contacted by the study team for a telephone interview.